Role of vascular endothelial growth factor in regulation of physiological angiogenesis

American Journal of Physiology - Cell Physiology

Volumn 280, Issue 6 49-6, 2001, Pages

  Ferrara, N ^a  

^a GENENTECH INC   (United States)

Author keywords

Apoptosis; Endothelium; Retinopathy; Tumor growth; Tyrosine kinases

Indexed keywords

ANGIOGENIC FACTOR; FLT3 LIGAND; TYROSINE KINASE RECEPTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ALLELE; ANGIOGENESIS; APOPTOSIS; EMBRYO MORTALITY; ENCHONDRAL OSSIFICATION; GENE INACTIVATION; HUMAN; LETHALITY; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; REPRODUCTION; RETINOPATHY; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; VASCULARIZATION;

EID: 0034979273     PISSN: 03636143     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpcell.2001.280.6.c1358     Document Type: Review

References (115)

1. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy
2. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders
3. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins
4. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity
5. Mapping of the sites for ligand binding and receptor dimerization at the extracellular domain of the vascular endothelial growth factor receptor FLT-1
6. The changes in the vascular pattern of the ovary of the albino rat during the estrous cycle
7. Vascular endothelial growth factor increases hydraulic conductivity of isolated perfused microvessels
8. 2+-dependent pathway
9. Mice lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia
10. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF
11. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal
12. A randomized phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus 5-fluorouracil/leucovorin (FU/LV) to FU/LV alone in patients with metastatic colorectal cancer
13. Vascular endothelial growth factor (VEGF) in cartilage neovascularization and chondrocyte differentiation: Auto-paracrine role during endochondral bone formation
14. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
15. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188
16. Intracerebral tumor-associated hemorrhage caused by overexpression of the vascular endothelial growth factor isoforms VEGF121 and VEGF165 but not VEGF189
17. Amino acid and cDNA sequences of a vascular endothelial cell mitogen that is homologous to platelet-derived growth factor
18. Vascular endothelial growth factor/vascular permeability factor expression in the rat uterus: Rapid stimulation by estrogen correlates with estrogen-induced increases in uterine capillary permeability and growth
19. Interaction of the Flt-1 tyrosine kinase receptor with the p85 subunit of phosphatidylinositol 3-kinase. Mapping of a novel site involved in binding
20. The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade
21. Mapping the charged residues in the second immunoglobulin-like domain of the vascular endothelial growth factor/placenta growth factor receptor Flt-1 required for binding and structural stability
22. A randomized phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC
23. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor
24. Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing
25. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis
26. Fibrin containing gels induce angiogenesis. Implications for tumor stroma generation and wound healing
27. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability
28. Vascular endothelial growth factor induces endothelial fenestrations in vitro
29. Role of vascular endothelial growth factor in the regulation of angiogenesis
30. Clinical applications of angiogenic growth factors and their inhibitors
31. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
32. Vascular endothelial growth factor is essential for corpus luteum angiogenesis
33. The biology of vascular endothelial growth factor
34. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells
35. Angiogenesis in cancer, vascular, rheumatoid and other disease
36. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium
37. Increased hemangioblast commitment, not vascular disorganization, is the primary defect in Flt-1 knock-out mice
38. Suppression of luteal angiogenesis in the primate after neutralization of vascular endothelial growth factor
39. Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor
40. Receptors for collapsin/semaphorins
41. Vascular endothelial growth factor induces expression of the antiapoptotic proteins. Bcl-2 and A1 in vascular endothelial cells
42. VEGF is required for growth and survival in neonatal mice
43. VEGF regulates endothelial cell survival by the PI3-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation
44. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation
45. Analysis of biological effects and signaling properties of Flt-1(VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants
46. A repressor sequence in the juxtamembrane domain of Flt-1 (VEGFR-1) constitutively inhibits VEGF-dependent PI 3 kinase activation and endothelial cell migration
47. A cardiac myocyte VEGF paracrine patheway is required to maintain cardiac function
48. Analysis of blood vessel maturation processes during cyclic ovarian angiogenesis
49. Production of a corpus luteum angiogenic factor responsible for proliferation of capillaries and neovascularization of the corpus luteum
50. Isoforms of vascular endothelial growth factor act in a coordinated fashion to recruit and expand tumor vasculature
51. Vasculotropin/vascular endothelial growth factor is an autocrine growth factor for human retinal pigment epithelial cells cultured in vitro
52. Conditional inactivation of VEGF-A in areas of collagen2a1 expression results in embryonic lethality in the heterozygous state
53. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice
54. The vascular endothelial growth factor family: Identification of a fourth molecular species and characterization of alternative splicing of RNA
55. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms
56. Human Muller cells express VEGF183, a novel spliced variant of vascular endothelial growth factor
57. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor
58. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR
59. The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency
60. Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis
61. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo
62. Vascular endothelial growth factor is an essential molecule for mouse kidney development: Glomerulogenesis and nephrogenesis
63. Signaling angiogenesis and lymphangiogenesis
64. Inducible gene targeting in mice
65. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor
66. Placenta growth factor stimulates MAP kinase and mitogenicity but not phospholipase C-gamma and migration of endothelial cells expressing Flt 1
67. Vascular endothelial growth factor is a secreted angiogenic mitogen
68. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes
69. Homologs of vascular endothelial growth factor are encoded by the poxvirus orf virus
70. Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PlGF), are transcribed from a single gene of chromosome 14
71. Angiopoietin-2, a natural antagonist for Tie-2 that disrupts in vivo angiogenesis
72. Detection of vascular endothelial growth factor mRNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy
73. A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit
74. A novel vascular endothelial growth factor encoded by orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases
75. Vasculotropin/vascular endothelial growth factor induces differentiation in cultured osteoblasts
76. Neuropilin-1 is a placenta growth factor-2 receptor
77. Vascular endothelial growth factor (VEGF) and its receptors
78. Effects of vascular endothelial growth factor on pancreatic duct cell replication and the insulin production of fetal islet-like cell clusters in vitro
79. A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain
80. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells
81. Signal relays in the VEGF system
82. Systemic activation of the vascular endothelial growth factor receptor KDR/flk-1 selectively triggers endothelial cells with an angiogenic phenotype
83. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR
84. The vascular endothelial growth factor isoforms (VEGF): Differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF
85. Vascular endothelial growth factor is expressed in rat corpus luteum
86. Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT20 cells
87. VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix
88. Humanization of an anti-VEGF monoclonal antibody for the therapy of solid tumors and other disorders
89. Vascular endothelial growth factor messenger ribonucleic acid expression in the primate ovary
90. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor
91. Neovasculature induced by vascular endothelial growth factor is fenestrated
92. Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody
93. A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF
94. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid
95. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice
96. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase (flt) closely related to the fms family
97. The mouse gene for vascular endothelial growth factor. Genomic structure, definition of the transcriptional unit, and characterization of transcriptional and post-transcriptional regulatory sequences
98. Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally-mediated angiogenesis
99. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
100. Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney
101. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor
102. Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system
103. Flk-1 as a target for tumor growth inhibition
104. Identification of a new endothelial cell growth factor receptor tyrosine kinase
105. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor
106. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing
107. Oxygen regulates vascular endothelial growth factor-mediated vasculogenesis and tubulogenesis
108. Regulation of angiogenesis via vascular endothelial growth factor receptors
109. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes
110. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor
111. Crystal structure at 1.7 A resolution of VEGF in complex with domain 2 of the Flt-1 receptor
112. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration
113. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody